A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Yung, W K A, Albright, R E, Olson, J, Fredericks, R, Fink, K, Prados, M D, Brada, M, Spence, A, Hohl, R J, Shapiro, W, Glantz, M, Greenberg, H, Selker, R G, Vick, N A, Rampling, R, Friedman, H, Phillips, P, Bruner, J, Yue, N, Osoba, D, Zaknoen, S, Levin, V A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363506/
https://www.ncbi.nlm.nih.gov/pubmed/10944597
http://dx.doi.org/10.1054/bjoc.2000.1316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363506/
https://www.ncbi.nlm.nih.gov/pubmed/10944597
http://dx.doi.org/10.1054/bjoc.2000.1316

Ejemplares similares